“Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma” (2018) SKIN The Journal of Cutaneous Medicine, 2, p. S77. doi:10.25251/skin.2.supp.77.